NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.57

-0.06 (-2.28%)

(As of 12/2/2022 03:00 PM ET)

Add

Compare

Today's Range: $2.56
▼
$2.68
50-Day Range: $1.99
▼
$2.66
52-Week Range: $1.96
▼
$3.36

Volume: 2,625 shs
Average Volume: 57,097 shs
Market Capitalization: $126.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

MediciNova MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 133.5% Upside
$6.00 Price Target
Short Interest: Healthy
1.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.48
Based on 4 Articles This Week
Insider Trading: Selling Shares
$15,870 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.20) to ($0.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

666th out of 1,052 stocks

Pharmaceutical Preparations Industry

323rd out of 514 stocks

3.5

Analyst's Opinion

Consensus Rating
MediciNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, MediciNova has a forecasted upside of 133.5% from its current price of $2.57.
Amount of Analyst Coverage
MediciNova has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.44% of the float of MediciNova has been sold short.
Short Interest Ratio / Days to Cover
MediciNova has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.
Change versus previous month
Short interest in MediciNova has recently decreased by 17.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MediciNova does not currently pay a dividend.
Dividend Growth
MediciNova does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNOV.

3.0

News and Social Media Coverage

News Sentiment
MediciNova has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for MediciNova this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for MNOV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
1 people have added MediciNova to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediciNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,870.00 in company stock.
Percentage Held by Insiders
16.70% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 25.41% of the stock of MediciNova is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MediciNova are expected to decrease in the coming year, from ($0.20) to ($0.37) per share.
Price to Book Value per Share Ratio
MediciNova has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

December 2, 2022 | americanbankingnews.com

Comparing UroGen Pharma (NASDAQ:URGN) and MediciNova (NASDAQ:MNOV)

November 18, 2022 | finance.yahoo.com

MNOV: Well Financed to Get Through Tough Market Conditions…

October 13, 2022 | finance.yahoo.com

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

October 6, 2022 | reuters.com

MNOV.A - MediciNova, Inc. | Stock Price & Latest News | Reuters

September 29, 2022 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

September 16, 2022 | seekingalpha.com

MediciNova to get US patent for MN-166 to treat brain cancer - Seeking Alpha

September 15, 2022 | globenewswire.com

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire

September 15, 2022 | finance.yahoo.com

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

September 15, 2022 | globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswire

September 14, 2022 | nasdaq.com

Health Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - Nasdaq

September 14, 2022 | finance.yahoo.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

September 14, 2022 | seekingalpha.com

MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders

September 14, 2022 | finance.yahoo.com

MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates

September 14, 2022 | finance.yahoo.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada - Yahoo Finance

September 13, 2022 | globenewswire.com

September 13, 2022 | finance.yahoo.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

August 24, 2022 | bizjournals.com

Braustin Homes appoints new executives amid a boom in business - San Antonio Business Journal - The Business Journals

August 23, 2022 | finance.yahoo.com

Global Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight - Yahoo Finance

August 19, 2022 | benzinga.com

Phase 2 Trial of MN-001 in Patients with NAFLD, Type 2 Diabetes, and Hypertriglyceridemia Underway

August 16, 2022 | seekingalpha.com

MediciNova's MN-166 to be part of study to treat Long COVID - Seeking Alpha

August 16, 2022 | globenewswire.com

MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID - GlobeNewswire

August 16, 2022 | finance.yahoo.com

MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID

August 9, 2022 | globenewswire.com

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation - GlobeNewswire

August 9, 2022 | finance.yahoo.com

July 27, 2022 | globenewswire.com

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea - GlobeNewswire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings: 10/26/2020
Today: 12/02/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/09/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNOV
CUSIP: N/A
CIK: 1226616
Web: medicinova.com
Phone: (858) 373-1500
Fax: 858-404-0048
Employees: 11
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +133.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,130,000.00
Net Margins: N/A
Pretax Margin: -2,628,577.25%
Return on Equity: -16.76%
Return on Assets: -15.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.74
Quick Ratio: 11.74

Sales & Book Value

Annual Sales: $4.04 million
Price / Sales: 31.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.49 per share
Price / Book: 1.72

Miscellaneous

Outstanding Shares: 49,050,000
Free Float: 40,855,000
Market Cap: $126.06 million
Optionable: Optionable
Beta: 0.90

Social Links

Key Executives

Dr. Yuichi Iwaki M.D. (Age 72)
Ph.D., Co-Founder, Pres, CEO & Exec. Director
Comp: $777.7k

Dr. Kazuko Matsuda M.D. (Age 56)
M.P.H., MPH, Ph.D., Chief Medical Officer & Director
Comp: $564.13k

Mr. Jason J. Kruger CPA (Age 45)
CFO & Principal Financial Officer

Dr. David H. Crean M.B.A. (Age 57)
Ph.D., Chief Bus. Officer

Mr. John O'Neil CPA
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.
What is MediciNova's stock price forecast for 2023?: 1 equities research analysts have issued twelve-month target prices for MediciNova's stock. Their MNOV share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 128.1% from the stock's current price.
View analysts price targets for MNOV or view top-rated stocks among Wall Street analysts.
How have MNOV shares performed in 2022?: MediciNova's stock was trading at $2.68 at the beginning of 2022. Since then, MNOV shares have decreased by 1.9% and is now trading at $2.63.
View the best growth stocks for 2022 here.
When is MediciNova's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our MNOV earnings forecast.
How were MediciNova's earnings last quarter?: MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04.

What other stocks do shareholders of MediciNova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).
What is MediciNova's stock symbol?: MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
Who are MediciNova's major shareholders?: MediciNova's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.45%), Barclays PLC (0.32%), Renaissance Technologies LLC (0.31%), Citadel Advisors LLC (0.05%) and Price T Rowe Associates Inc. MD (0.04%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends.
How do I buy shares of MediciNova?: Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MediciNova's stock price today?: One share of MNOV stock can currently be purchased for approximately $2.63.
How much money does MediciNova make?: MediciNova (NASDAQ:MNOV) has a market capitalization of $129.00 million and generates $4.04 million in revenue each year.
How can I contact MediciNova?: MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MediciNova - MNOV Stock Forecast, Price & News

MediciNova MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MediciNova (NASDAQ:MNOV) Stock

MNOV Stock News Headlines

MNOV Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MNOV Stock - Frequently Asked Questions

Overall MarketRank^™